AllianceBernstein
TRDA icon

AllianceBernstein’s Entrada Therapeutics TRDA Stock Holding History

AllianceBernstein’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$399K Buy
31,640
+7,320
+30% +$70.2K ﹤0.01% 2847
2026
Q1 		$250K Hold
24,320
– – ﹤0.01% 2960
2025
Q4 		$250K Hold
24,320
– – ﹤0.01% 2980
2025
Q3 		$141K Buy
24,320
+1,620
+7% +$9.48K ﹤0.01% 3144
2025
Q2 		$153K Buy
22,700
+9,930
+78% +$79.9K ﹤0.01% 3111
2025
Q1 		$115K Hold
12,770
– – ﹤0.01% 3046
2024
Q4 		$221K Hold
12,770
– – ﹤0.01% 3003
2024
Q3 		$204K Buy
12,770
+2,550
+25% +$40.2K ﹤0.01% 3038
2024
Q2 		$146K Buy
+10,220
New +$145K ﹤0.01% 3074

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

AllianceBernstein's TRDA Position: Q2 2026 in Review

AllianceBernstein increased its Entrada Therapeutics (TRDA) stake by 30% in Q2 2026, buying an estimated $70.2K and bringing the position to 31,640 shares worth $399K. The position accounts for ﹤0.01% of the portfolio, ranked #2847.

AllianceBernstein first reported a position in TRDA in Q2 2024 and has held it in 9 quarters since. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • AllianceBernstein held 31,640 shares of Entrada Therapeutics worth $399K as of Q2 2026.
  • AllianceBernstein bought 7,320 Entrada Therapeutics shares in Q2 2026, an estimated $70.2K.
  • Entrada Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2847 holding.
  • AllianceBernstein first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.